Samalizumab

Samalizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD200
Clinical data
ATC code	none;
Identifiers
CAS Number	1073059-33-2 ;
ChemSpider	none;
UNII	64EUX713G6;
KEGG	D09961 ;
Chemical and physical data
Formula	C6542H10086N1702O2102S46
Molar mass	147687.22 g·mol−1
	(what is this?) (verify)

Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1] Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. [2]

Samalizumab was developed by Alexion Pharmaceuticals.

References

"Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.
"Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200". J Immunother Cancer 2019 Aug 23;7(1):227. doi: 10.1186/s40425-019-0710-.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.

[2] "Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200". J Immunother Cancer 2019 Aug 23;7(1):227. doi: 10.1186/s40425-019-0710-.